MARKET

NTLA

NTLA

Intellia Therape
NASDAQ
12.37
-0.87
-6.57%
After Hours: 12.33 -0.04 -0.32% 19:58 03/27 EDT
OPEN
13.12
PREV CLOSE
13.24
HIGH
13.16
LOW
12.12
VOLUME
3.74M
TURNOVER
--
52 WEEK HIGH
28.25
52 WEEK LOW
5.90
MARKET CAP
1.46B
P/E (TTM)
-3.2484
1D
5D
1M
3M
1Y
5Y
1D
Bank of America Securities Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA)
TipRanks · 3d ago
Weekly Report: what happened at NTLA last week (0316-0320)?
Weekly Report · 4d ago
Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value
Seeking Alpha · 03/17 13:38
Weekly Report: what happened at NTLA last week (0309-0313)?
Weekly Report · 03/16 09:51
KalVista Pharmaceuticals: Has Potential But With Caveats
Seeking Alpha · 03/12 15:07
Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here's My Take
Seeking Alpha · 03/09 20:07
Intellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory
Seeking Alpha · 03/09 15:28
Cathie Wood's weekly recap: adds to AMZN, BABA, HOOD, COIN, cuts TSM, BIDU
Seeking Alpha · 03/09 11:10
More
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase 3 development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.

Webull offers Intellia Therapeutics Inc stock information, including NASDAQ: NTLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NTLA stock methods without spending real money on the virtual paper trading platform.